马伐卡坦对肥厚型心肌病患者超声心动图参数、心脏功能和生物标志物的影响：一项系统评价和荟萃分析
The effect of mavacamten on echocardiographic parameters, cardiac function and biomarkers in hypertrophic cardiomyopathy patients, a systematic review and meta-analysis.
作者信息
Otmani Zina, Abdrabou Noura, Elsayed Hazem Ayman, Yassin Mazen Negmeldin Aly, Abouzid Mohamed, Hindawi Mahmoud Diaa, Awad Ayman K
机构信息
Faculty of Medicine, Mouloud Mammeri University, Tizi Ouzou, Algeria; Medical Research Group of Egypt, Negida Academy, Arlington, MA, USA.
Faculty of Medicine, Alexandria University, Alexandria, Egypt; Medical Research Group of Egypt, Negida Academy, Arlington, MA, USA.
出版信息
Indian Heart J. 2025 Jul-Aug;77(4):290-302. doi: 10.1016/j.ihj.2025.05.011. Epub 2025 May 27.
BACKGROUND
Evaluate the effect of mavacamten on echocardiographic parameters and cardiac biomarkers in patients with hypertrophic cardiomyopathy (HCM).
METHODS
We searched PubMed, SCOPUS, Web of Science, and Cochrane Library until November 2023. Results were reported as mean difference (MD) and Risk Ratio (RR) with 95 % confidence intervals (CI).
RESULTS
Seven studies with 524 patients (456 with obstructive HCM and 59 with non-obstructive HCM) were included. Mavacamten significantly improved septal early diastolic mitral annular velocity (e') (MD 0.78, 95 % CI [0.51 to 1.05]) and left ventricular mass index (LVMI). It reduced left ventricular outflow tract (LVOT) gradient, NT-proBNP (MD -557.14, 95 % CI [-685.59 to -428.68]), and troponin levels. Improvements were also seen in left atrial volume index (MD -6.26, 95 % CI [-8.88 to -3.63]) and E/e' ratios, particularly in obstructive HCM patients.
CONCLUSION
Mavacamten enhances echocardiographic and cardiac biomarker outcomes in HCM patients on short-term follow-up. Limited data on non-obstructive HCM require cautious interpretation.
背景
评估马伐卡坦对肥厚型心肌病（HCM）患者超声心动图参数和心脏生物标志物的影响。
方法
我们检索了截至2023年11月的PubMed、SCOPUS、科学网和考克兰图书馆。结果以平均差（MD）和风险比（RR）以及95%置信区间（CI）报告。
结果
纳入了7项研究，共524例患者（456例梗阻性HCM患者和59例非梗阻性HCM患者）。马伐卡坦显著改善了室间隔舒张早期二尖瓣环速度（e'）（MD 0.78，95%CI[0.51至1.05]）和左心室质量指数（LVMI）。它降低了左心室流出道（LVOT）梯度、N末端B型利钠肽原（NT-proBNP）（MD -557.14，95%CI[-685.59至-428.68]）和肌钙蛋白水平。左心房容积指数（MD -6.26，95%CI[-8.88至-3.63]）和E/e'比值也有所改善，尤其是在梗阻性HCM患者中。
结论
在短期随访中，马伐卡坦可改善HCM患者的超声心动图和心脏生物标志物结果。关于非梗阻性HCM的有限数据需要谨慎解读。
Zotero 插件